Molbio Diagnostics IPO
Molbio Diagnostics IPO
Overview
Molbio Diagnostics IPO is a book build issue of ₹939.70 crores. The issue is a combination of fresh issue of 0.25 crore shares aggregating to ₹200.00 crores and offer for sale of 0.92 crore shares aggregating to ₹739.70 crores. Molbio Diagnostics IPO opens for subscription on Aug 10, 2026 and closes on Aug 12, 2026. The allotment for the Molbio Diagnostics IPO is expected to be finalized on Aug 13, 2026. Molbio Diagnostics IPO will list on NSE and BSE with a tentative listing date fixed as Aug 17, 2026. Molbio Diagnostics IPO is set issue price band at ₹768 to ₹807 per share. The lot size for an application is 18 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,526 (18 shares) (based on upper price). Kotak Mahindra Capital Co.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Total Shares
1,16,46,246
Issue Size
₹940 Cr
Price Band
₹768 – ₹807
Lot Size
18 shares
Min. Investment
₹14,526
Max. Investment
₹1,88,838
Open Date
10 Aug, 2026
Close Date
12 Aug, 2026
Allotment
13 Aug, 2026
Listing
17 Aug, 2026
Max. Investment
₹1,88,838
Announced
10 Aug, 2026
Opening Date
10 Aug, 2026
Closing Date
12 Aug, 2026
Basis of Allotment
13 Aug, 2026
Initiation of Refunds
14 Aug, 2026
Credit of Shares
14 Aug, 2026
Listing Date
17 Aug, 2026
Live GMP
Est. Listing: ₹931
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Molbio Diagnostics IPO
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
Molb
Molbio Diagnostics IPO Share Price
Issue Breakdown
Shareholding
Dilution: 2.2% increase in shares
Molbio Diagnostics IPO Financial Health
Molbio Diagnostics Ltd.'s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.
Molbio Diagnostics IPO Lot Size
Investors can bid for a minimum of 18 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹1,88,838 |
| S-HNI (Min) | 14 | 252 | ₹2,03,364 |
| S-HNI (Max) | 68 | 1224 | ₹9,87,768 |
| B-HNI (Min) | 69 | 1242 | ₹10,02,294 |
(All values in CR)
Molbio Diagnostics IPO Valuations
| Metric | Value |
|---|---|
| ROE | 15.59 |
| ROCE | 17.55 |
| RoNW | 14.55 |
| PAT Margin | 11.28 |
| EBITDA Margin | 22.56 |
| NAV | 101.51 |
(All values in CR)
Molbio Diagnostics IPO Strength & Risk
Molbio Diagnostics IPO Strengths
- Strong position in the point-of-care molecular diagnostics market with its proprietary Truenat platform.
- Truenat is one of only two rapid molecular diagnostic platforms globally endorsed by the WHO for initial detection of tuberculosis and rifampicin resistance.
- Broad diagnostic portfolio covering diseases including TB, COVID-19, hepatitis, HIV and HPV.
- Integrated capabilities across research & development, manufacturing and distribution of diagnostic devices and test kits.
- Established international presence, with Truenat deployed across several countries and plans to expand further in Africa, Southeast Asia, Latin America, the US and Europe.
- Strong financial growth, with FY25 revenue from operations of about ₹1,020 crore, up around 22% YoY, and PAT of about ₹138.5 crore.
Molbio Diagnostics IPO Risks
- Significant dependence on government healthcare programmes and international aid agencies, exposing the business to changes in public-health spending and procurement policies.
- Revenue concentration in tuberculosis-related diagnostic products could make performance vulnerable to changes in TB testing demand.
- Dependence on a limited number of large customers creates customer concentration risk.
- Diagnostic products require regulatory approvals, and delays or failure to obtain approvals could affect new product launches and expansion.
- International expansion exposes the company to different regulatory requirements and execution risks across markets.
- A substantial part of the IPO consists of an Offer for Sale (OFS), and proceeds from those shares will go to selling shareholders rather than the company.
Molbio Diagnostics IPO Subscriptions Status
Molbio Diagnostics IPO subscribed 1.22 times. The public issue subscribed 1.26 times in the retail category, 1.00 times in QIB (Ex Anchor), and 1.37 times in the NII category by August 11, 2026 10:53:53 AM (Day 2).
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Rs Cr.) |
|---|---|---|---|---|
| Anchor | 1.00 | 34,87,717 | 34,87,717 | 281.459 |
| QIB (Ex Anchor) | 1.00 | 23,25,146 | 23,33,574 | 188.319 |
| NII | 1.37 | 17,43,859 | 23,87,520 | 192.673 |
| bNII (> ₹10L) | 1.22 | 11,62,573 | 14,18,400 | 114.465 |
| sNII (< ₹10L) | 1.67 | 5,81,286 | 9,69,120 | 78.208 |
| Retail | 1.26 | 40,69,004 | 51,38,316 | 414.662 |
| Employees | 2.69 | 20,520 | 55,170 | 4.452 |
| Total | 1.22 | 81,58,529 | 99,14,580 | 800.107 |
Molbio Diagnostics IPO GMP
Molbio Diagnostics IPO last GMP is ₹124, last updated Aug 11th 2026 09:53 AM. With the upper price band of ₹807.00, Molbio Diagnostics IPO's estimated listing price is ₹931 (cap price + today's GMP). The expected percentage gain/loss per share is 15.37%. >> Molbio Diagnostics IPO Retail Subject to Sauda: ₹1700 >> Molbio Diagnostics IPO Small HNI Subject to Sauda: ₹23800 During this period, the GMP ranged from a low of ₹0.00 to a high of ₹220.00.
Last updated 11 Aug, 2026 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 11 Aug, 2026 | 807 | ₹124▼ | - | ₹931 (15.37%) | 2232 | 11 Aug, 2026 |
| 10 Aug, 2026 | 807 | ₹127▼ | - | ₹934 (15.74%) | 2286 | 10 Aug, 2026 |
| 09 Aug, 2026 | 807 | ₹132▲ | - | ₹939 (16.36%) | 2376 | 09 Aug, 2026 |
| 08 Aug, 2026 | 807 | ₹130▼ | - | ₹937 (16.11%) | 2340 | 08 Aug, 2026 |
| 07 Aug, 2026 | 807 | ₹180▼ | - | ₹987 (22.30%) | 3240 | 07 Aug, 2026 |
| 06 Aug, 2026 | 807 | ₹220▲ | - | ₹1027 (27.26%) | 3960 | 06 Aug, 2026 |
| 05 Aug, 2026 | 807 | ₹170▲ | - | ₹977 (21.07%) | 3060 | 05 Aug, 2026 |
| 04 Aug, 2026 | 0 | ₹0 | - | ₹ (%) | - | 04 Aug, 2026 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Molbio Diagnostics IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Molbio Diagnostics IPO under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.